annual cash & cash equivalents:
$314.02M+$85.66M(+37.51%)Summary
- As of today (September 13, 2025), SPRY annual cash & cash equivalents is $314.02 million, with the most recent change of +$85.66 million (+37.51%) on December 31, 2024.
- During the last 3 years, SPRY annual cash & cash equivalents has risen by +$253.96 million (+422.82%).
- SPRY annual cash & cash equivalents is now -18.77% below its all-time high of $386.57 million, reached on December 1, 2020.
Performance
SPRY Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$240.13M-$35.60M(-12.91%)Summary
- As of today (September 13, 2025), SPRY quarterly cash & cash equivalents is $240.13 million, with the most recent change of -$35.60 million (-12.91%) on June 30, 2025.
- Over the past year, SPRY quarterly cash & cash equivalents has increased by +$21.39 million (+9.78%).
- SPRY quarterly cash & cash equivalents is now -37.88% below its all-time high of $386.57 million, reached on December 1, 2020.
Performance
SPRY quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SPRY Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.5% | +9.8% |
| 3 y3 years | +422.8% | -6.9% |
| 5 y5 years | +3047.8% | - |
SPRY Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +422.8% | -23.5% | +17.4% |
| 5 y | 5-year | -18.8% | +3047.8% | -37.9% | +17.4% |
| alltime | all time | -18.8% | +3047.8% | -37.9% | +2307.1% |
SPRY Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $240.13M(-12.9%) |
| Mar 2025 | - | $275.73M(-12.2%) |
| Dec 2024 | $314.02M(+37.5%) | $314.02M(+53.5%) |
| Sep 2024 | - | $204.62M(-6.5%) |
| Jun 2024 | - | $218.74M(-2.2%) |
| Mar 2024 | - | $223.63M(-2.1%) |
| Dec 2023 | $228.36M(-16.8%) | $228.36M(-5.6%) |
| Sep 2023 | - | $241.90M(-4.1%) |
| Jun 2023 | - | $252.21M(-4.7%) |
| Mar 2023 | - | $264.55M(-0.8%) |
| Dec 2022 | $274.38M | - |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $266.62M(+3.4%) |
| Jun 2022 | - | $257.98M(+1.6%) |
| Mar 2022 | - | $253.85M(-0.1%) |
| Dec 2021 | $60.06M(-84.5%) | - |
| Dec 2021 | - | $254.04M(-15.5%) |
| Sep 2021 | - | $300.66M(-16.4%) |
| Jun 2021 | - | $359.69M(-3.9%) |
| Mar 2021 | - | $374.20M(-3.2%) |
| Dec 2020 | $386.57M(+3775.0%) | $386.57M(+3775.0%) |
| Dec 2019 | $9.98M(-50.5%) | $9.98M |
| Dec 2018 | $20.16M | - |
FAQ
- What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of SPRY is $314.02M
What is the all time high annual cash & cash equivalents for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $386.57M
What is ARS Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, SPRY annual cash & cash equivalents has changed by +$85.66M (+37.51%)
What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of SPRY is $240.13M
What is the all time high quarterly cash & cash equivalents for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $386.57M
What is ARS Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, SPRY quarterly cash & cash equivalents has changed by +$21.39M (+9.78%)